FDA+ roundup: BsUFA III ready for showtime, court tells FDA to re-work compounding plan, new guidance updates and more
The FDA has now spelled out what exactly will be included in the third iteration of Biosimilar User Fee Act (BsUFA) from 2023 through 2027, which similarly to the prescription drug deal, sets fees that industry has to pay for submitting applications, in exchange for firm timelines that the agency must meet.
This latest deal includes several sweeteners for the biosimilar industry, which has yet to make great strides in the US market, with shorter review timelines for safety labeling updates and updates to add or remove an indication that does not contain efficacy data.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.